| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01021423 Details | 2019-11-19 Interventional | 3 | 9 | Lenalidomide Lymphoma Lymphoma, Mantl… Lymphoma, Non-H… Mantle Cell Lym… Non-Hodgkin's L… | Terminated by sponsor due to new unpublished data that rendered the current design of the study
no longer clinically relevant. There were no safety concerns. Study terminated early. Most analyses were not performed. | |||
| NCT00670748 Details | 2019-11-19 Interventional | 2 | 45 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Carcinoma, Rena… Melanoma Neoplasm Metast… Neoplasms Neoplasms, Seco… Metastatic Canc… Metastatic Mela… Metastatic Rena… | A more highly selected protocol with ESO TCR opened for pts with melanoma - | |||
| NCT00537511 Details | 2019-11-19 Interventional | 1/2 | [1 Refs] | 22 | Etoposide Etoposide phosp… Pomalidomide Carcinoma, Smal… | This study was terminated for administrative reasons. - | ||
| NCT03665350 2018-001057-26 Details | 2019-11-18 Interventional | 2 | 10 | Insulin Diabetes Mellit… Diabetes Mellit… Heart Failure | Insulin-HF study was prematurely ended due principally to low recruitment rate. - | |||
| NCT02853071 Details | 2019-11-18 Interventional | 2 | 0 | Estramustine Breast Neoplasm… Breast Cancer | withdrawal industrial - | |||
| NCT02452970 Details | 2019-11-15 Interventional | 2 | 4 | Gemcitabine Cholangiocarcin… | Resensitization or clinical benefit was not observed - | |||
| NCT02343939 2016-003353-16 Details | 2019-11-15 Interventional | 1/2 | 148 | Azacitidine Cytarabine Daunorubicin Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | - - | |||
| NCT02299115 Details | 2019-11-14 Interventional | 3 | 0 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Vigabatrin Spasm Spasms, Infanti… Infantile Spasm… | Most centres are now using oral steroids as 1st line treatment so question of efficacy is no
longer of high interest. - | |||
| NCT00531271 Details | 2019-11-14 Interventional | 1/2 | - | Docetaxel Breast Neoplasm… Metastatic Brea… | - - | |||
| NCT00529373 Details | 2019-11-14 Interventional | 3 | 16071 | Calcium Calcium Carbona… Calcium, Dietar… Cholecalciferol Vitamin D Osteoporosis Osteoporosis, P… Postmenopausal … | - The study was terminated early due to an observed increase in risk of stroke in Protocol MK-0822-018. | |||
| NCT00109109 Details | 2019-11-14 Interventional | 1 | [1 Refs] | - | Vorinostat Multiple Myelom… Neoplasms, Plas… | - - | ||
| NCT03675854 Details | 2019-11-13 Interventional | 4 | 0 | Cefazolin Peritonitis Peritoneal Dial… | New data from another study show that a positive result is unlikely. - | |||
| NCT01118975 Details | 2019-11-13 Interventional | 1/2 | 12 | Lapatinib Vorinostat Breast Neoplasm… Neoplasm Metast… Breast Cancer | Lost sponsorship for study drug The most important limitation of this study is that the Phase II efficacy portion was terminated early by the sponsor. | |||
| NCT03477864 Details | 2019-11-12 Interventional | 1 | 0 | Antibodies Antibodies, Mon… Antineoplastic … Cemiplimab Immunoglobulins Ipilimumab Prostatic Neopl… Stage III Prost… Stage IIIA Pros… Stage IIIB Pros… Stage IIIC Pros… Stage IV Prosta… Stage IVA Prost… Stage IVB Prost… | Study was not accruing - | |||
| NCT02661815 Details | 2019-11-08 Interventional | 1 | 6 | Bevacizumab Paclitaxel Ricolinostat Fallopian Tube … Fallopian Tube … Ovarian Cancer Primary Periton… | Company decided not to move forward with further accrual. - | |||
| NCT02741076 Details | 2019-11-06 Interventional | 4 | 44 | Analgesics, Opi… Morphine Oxycodone Oxymorphone Chronic Pain Narcotic-Relate… Opioid-Related … Substance-Relat… Drug Abuse Narcotic Abuse Opiate Addictio… | Inability to recruit sufficient no. of subjects over an acceptable time period This study was terminated because it could not recruit the planned study population. Randomized study participants were too few to show changes in pain intensity scores or clinical effects. The safety profile reflects current prescribing information. | |||
| NCT03678792 Details | 2019-11-05 Interventional | 3 | 0 | Buprenorphine Buprenorphine, … Morphine Naloxone Tramadol Opioid-Related … Opioid Withdraw… | Infeasible to conduct at this time. - | |||
| NCT03154333 Details | 2019-11-05 Interventional | 2 | 54 | Diacerein Epidermolysis B… Epidermolysis B… | Futility - | |||
| NCT02289222 Details | 2019-11-05 Interventional | 1/2 | 48 | Dexamethasone Pembrolizumab Pomalidomide Multiple Myelom… Neoplasms, Plas… | Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the
study. - | |||
| NCT00730847 2017-000458-20 Details | 2019-11-05 Interventional | 4 | 743 | Vaccines Papillomavirus … Human Papilloma… | GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study. - |